Impact Factor 6.244 | CiteScore 3.9
More on impact ›


Front. Oncol., 04 June 2021 |

LpCat1 Promotes Malignant Transformation of Hepatocellular Carcinoma Cells by Directly Suppressing STAT1

  • 1Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Centre for Liver Cancer, Navy Military Medical University, Shanghai, China
  • 2Department of General Surgery, Shanghai Sixth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Hepatocellular carcinoma (HCC) is a malignant cancer with rapid proliferation and high metastasis ability. To explore the crucial genes that maintain the aggressive behaviors of cancer cells is very important for clinical gene therapy of HCC. LpCat1 was reported to be highly expressed and exert pro-tumorigenic effect in a variety of cancers, including HCC. However, its detailed molecular mechanism remained unclear. In this study, we confirmed that LpCat1 was up-regulated in HCC tissues and cancer cell lines. The overexpressed LpCat1 promoted the proliferation, migration and invasion of HCC cells, and accelerated cell cycle progression, while knocking down LpCat1 significantly inhibited cell proliferation, migration and invasion in vitro and in vivo, and arrested HCC cells at G0/G1 phase. Moreover, we proved for the first time that LpCat1 directly interacted with STAT1 which was generally recognized as a tumor suppressor in HCC. High levels of LpCat1 in HCC could inhibit STAT1 expression, up-regulate CyclinD1, CyclinE, CDK4 and MMP-9, and decrease p27kip1 to promote cancer progression. Conversely, down-regulation of LpCat1 would cause the opposite changes to repress the viability and motility of HCC cells. Consequently, we concluded that LpCat1 was a contributor to progression and metastasis of HCC by interacting with STAT1.


Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Many factors, such as activation of oncogenes and inactivation of tumor suppressor genes, could cause unrestricted growth of HCC cells. Among them, hundreds of cancer-associated genes are closely related to the occurrence and development of HCC. With the development of a variety of “omics” technologies such as genomics, proteomics and transcriptomics, accumulating molecular markers related to malignant transformation of HCC cells have been discovered. Therefore, further study of HCC-related genes and identifying novel treatment targets have become an urgent task.

LpCat1 (lysophosphatidylcholine acyltransferase 1) is a key enzyme in phospholipid metabolism, which is responsible for promoting the synthesis and remodeling of phosphatidylcholine (PC) (1, 2). As the main component of cell membranes, PC plays an important role in maintaining cell structure and biological functions (3, 4). Previous studies have been reported that PC was involved in the malignant progression of many cancers (5). The expression of LpCat1 was obviously increased in various tumors including prostate cancer, gastric cancer and breast cancer (68). Its high expression is positively correlated with the development of malignant tumors. Emerging evidence showed that up-regulation of LpCat1 promotes cancer cell proliferation and metastasis, while knocking down LpCat1 could inhibit growth of cancer cells by inducing cell cycle arrest at G0/G1 phase, which may serve as a novel target of aggressive progression in oral squamous cell carcinoma (OSCC), renal clear cell carcinoma and lung adenocarcinoma (911). In HCC cells, LpCat1 overexpression enriched PCs and promoted cell proliferation, migration, and invasion (12). However, the detailed molecular mechanism remains poorly understood.

In the present study, we firstly confirmed that LpCat1 was overexpressed in the tissues and cells of HCC. Furthermore, we investigated the functional effect of up- or down-regulation of LpCat1 on the proliferation, metastasis and cell cycle of HCC cells. Based on identification of LpCat1 interactors by mass spectrometry, we confirmed that LpCat1 could directly interact with STAT1. As we known, STAT1 is generally recognized as a tumor suppressor gene in cancer cells (1315). Our data suggested that LpCat1 might promote the progression and metastasis of HCC by directly interacting with STAT1.

Materials and Methods

Human HCC Tissue Samples and Cell Lines

The clinical tissue samples were collected from HCC patients who underwent radical resection in our hospital. Informed consents have been signed for all the patients. Tissue microarray including 90 pairs of HCC tissue samples (including paired tumorous tissues and adjacent liver tissues) was detected by immunohistochemistry. Human HCC cell lines Huh7, Hep3B, HepG2, HCCLM3 and immortalized normal liver cell L02 were purchased from Chinese Academy of Sciences Cell Bank (Shanghai, China). The cells were cultured in DMEM medium with 10% FBS (Gibco, USA), 100 units/mL penicillin, 100 μg/mL streptomycin (Invitrogen, USA) and incubated in a CO2 incubator at 37°C.

Establishment of Stable LpCat1 Overexpressing and Knockdown HCC Cell Sublines

LpCat1 was stably overexpressed and knocked down in the human HCC cell lines Hep3B and Huh7 by means of lentiviral approach. Briefly, lentiviral-mediated LpCat1 overexpression vector (LpCat1 OV) and the null control vector (O Control) were constructed by inserting the coding sequence of LpCat1 (Gene ID: 79888) or nonsense sequence into lentivirus vector. The shRNA1, shRNA2, shRNA3 of LpCat1 and scramble shRNA were designed and constructed into lentivirus shRNA knockdown vectors. The sequences of three shRNAs were shown in Supplementary Table 1. According to knockdown effect of LpCat1 confirmed by western blot and qRT-PCR, shRNA1 of LpCat1 (LpCat1 KD) was chose for subsequent experiments. The scramble shRNA (K Control) was used as control. All lentivirus vectors carried U6 promoter, EGFP gene and puromycin resistance gene, cellular immunofluorescence was used to observe EGFP positive HCC cells at 72 h after infection (Supplementary Figure 1). The stably transfected cells selected by puromycin were used for all the in vitro and in vivo experiments.

RNA Extraction and Quantitative Polymerase Chain Reaction (qPCR)

Total RNA from HCC tissues (n=40) and cell lines were extracted by using TRIzol reagent. Complementary DNA (cDNA) was synthesized from 1 μg total RNA using Eastep RT Master Mix Kit (Promega, shanghai, China), and PCR was performed using Eastep qPCR Master Mix Kit (Promega, shanghai, China). PCR was run on the StepOne Plus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), and the transcript amounts for the target genes were estimated from the respective standard curves and normalized to the glyceraldehyde-3-phospate dehydrogenase (GAPDH). The primer sequences involved in this study were shown in Supplementary Table 2.

Western Blotting and Immunohistochemistry (IHC)

For western blotting, HCC cells were lysed with RIPA lysis buffer (1% PMSF, 1% phosphatase inhibitor and 1% protease inhibitor were added). The antibody information was shown in Supplementary Table 3.

For IHC, the tissue sections were incubated with the anti-LpCat1 antibody (Abcam) at 4°C overnight. Negative controls were performed by replacing the primary antibody with PBS. Then the sections were incubated with the horseradish peroxidase (HRP)-conjugated secondary antibody (Maixin-Bio, Fuzhou, China) at room temperature for 1 h, and the immunoreactivity was detected utilizing diaminobenzidine (DAB) substrate (Maixin-Bio). Counter-staining of the nucleus was performed using hematoxylin. The assessment of the staining was conducted by two investigators independently.

A quick scoring system that is the product of the intensity and percentage of the positive signal was used to calculate the LpCat1 IHC scores. Briefly, a signal of 0 indicated no staining, 1 indicated weak staining, 2 indicated intermediate staining and 3 indicated strong staining. Percentage scores were assigned as follows: 0 corresponded to 0%, 1 to 1-25%, 2 to 26-50%, 3 to 51-75%, and 4 to > 75%. The product of two terms rangs from 0 to 12, and the median value of total staining scores was identified as the optimal cut-off value. If the evaluated score was lower than the median, the indicator expression of in those HCC samples was classified as low; otherwise, it was classified as high (16).

Cell Proliferation and Clone Formation Assays

CCK8 assay was carried out to detect the proliferation ability of different experimental groups in vitro. Clone formation assay was used to evaluate the clone formation ability in vitro. The specific experimental procedures were carried out as previously described (17). All experiments were repeated at least three times.

Migration and Invasion Assay

In vitro cell migration and invasive abilities were measured by transwell assay. In brief, totally 3 × 104 cells were added onto the upper chamber, uncoated for migration assay, or coated with a thin layer of BD Matrigel Matrix (BD Biocsciences, MD) for invasion assay. After culture for 48 h, the migrated and invaded cells were fixed with 4% formaldehyde and subsequently stained with 0.1% crystal for assessment. For each experimental group, five random fields of stained cells were photographed and counted. All experiments were repeated at least three times.

Wound-Healing Assay

In vitro cell mobility was evaluated by wound-healing assay. In brief, cells were seeded in 6-well plate. The scratches were observed and images were captured with a microscope at 0 and 72 h pro-injury. Image-J software was used to determine the average area.

Cell Cycle

For cell cycle analysis, cells (1×106 cells per well) were seeded into 6-well plates, cultured for 48 h, washed twice with cold PBS, stained with propidium iodide (PI) and Annexin V, then examined cell cycle by flow cytometer (FACS420, BD Biosciences, San Jose, CA) within 2 h.

Immunoprecipitation Tandem Mass Spectrometry (IP-MS) and Co-IP Assay

To define the proteins which interacted with LpCat1, we performed IP-MS assay. Proteins of Huh7 cells stably transfected with LpCat1 overexpressed and null control vectors were collected. Immunoprecipitations was done by incubating the cell lysate (1 mg) with the anti-LpCat1 antibody (1μg) overnight at 4°C. Protein A/G Sepharose beads (Santa Cruz Biotechnology) were added to the lysate antibody solution for 2 h of incubation. Then, beads were washed and boiled in 5× SDS sample buffer. IPs for mass spectrometry were separated by SDS-PAGE and coomassie blue stained, the bands were retrieved and analyzed by MS. Liquid chromatography/mass spectrometry (LC/MS) was performed on a Thermo ScientificTM Q Exactive Plus coupled to an ultra-high performance liquid chromatography unit (Thermo Scientific Dionex Ultimate 3000) via a Nanospray Flex Ion Source (Thermo Fisher Scientific).

Co-IP assay was performed to verify the interaction between LpCat1 and STAT1. HCC cells with LpCat1 overexpressed and negative control vector were lysed in IP lysis buffer (#P0013, Beyotime Biotechnology). Then the lysates were incubated with the anti-LpCat1 and anti-STAT1 antibodies separately overnight at 4°C. Protein A/G-agarose beads were added for 2 h. The beads were collected and washed with lysis buffer for three times. The precipitated proteins were eluted and denatured in 5 × SDS loading buffer and analyzed by western blotting.

The Xenograft Assay and Metastasis Assay In Vivo

The xenograft model and metastasis model were established by implantation of stably-transfected Hep3B cell lines. Mice were handled and housed according to protocols approved by the Animal Ethics Committee of Navy Military Medical University (Shanghai, China).

For in vivo metastasis assay, 1 × 106 Hep3B cells stably transfected with different constructs were suspended in 100 μL of serum-free DMEM per male BALB/c-nu/nu mice, and injected into nude mice through the tail vein (6 mice per group). After four weeks, mice were sacrificed, and their lungs were dissected. Lung metastasis was diagnosed visual inspection and confirmed by histological staining.

For the xenograft model, 1 × 107 Hep3B cells of different groups were subcutaneously injected into left flank of 4-week-old male mice, respectively. Two month later, the subcutaneous tumor was removed and cut into pieces of the same size as 1 mm3. Twenty-four male BALB/C nude mice at 4-week-old (Shanghai SLAC Laboratory Animal Center of Chinese Academy of Sciences, Shanghai, China) were randomly divided into four groups (n = 6 per group) and the tumor pieces were implanted into the livers of each group to mimic the primary HCC. Six weeks later, mice were sacrificed and the tumors were harvested. Tumor weight was weighed, and tumor volume was calculated using the formula ‘‘a×b2×0.5’’, in which a and b represent the maximal and minimal diameters. The tumor specimens were fixed with phosphate-buffered neutral formalin, and prepared for examining the expression of LpCat1, STAT1, CyclinD1, ki67 and MMP-9 by immunohistochemical analysis.

Statistical Analysis

The results were presented as mean ± standard deviation (SD). Statistical evaluation of the data was performed with one-way ANOVA. Comparisons between two groups were made by using the paired t test. The P value less than 0.05 was considered statistically significant. All the statistical analyses were analyzed with SPSS version 19.0 software.


LpCat1 Was Frequently Up-Regulated In Human HCC Tissues and HCC Cell Lines

We examined 90 pairs of clinical HCC tissues by IHC, and found the expression of LpCat1 was dramatically elevated in HCC tissues, comparing with the para-cancerous tissues (Figure 1A). Correspondingly, LpCat1 was proved to be also up-regulated in HCC tissues by qRT-PCR and western blotting assay (Figure 1B, Supplementary Figure 2). After statistical analysis, the LpCat1 IHC scores in HCC tissues were obviously higher than those in normal liver tissues. 63 of 90 (70%) HCC samples were considered as LpCat1-high expression group. We then analyzed the correlation between LpCat1 protein expression and the clinicopathological characteristics of the patients with HCC (Supplementary Table 4). Among the clinical classifications, high expression level of LpCat1 in HCC tissues were significantly correlated with vascular invasion (p = 0.002) and TNM stage (p = 0.015). The results indicated that abnormal expression level of LpCat1 may be associated with the progression and metastasis of HCC.


Figure 1 LpCat1 was frequently up-regulated in human HCC tissues and HCC cell lines. (A) The expression level of LpCat1 was detected by immunohistochemical (IHC) analysis in HCC microarray. The representative images of LpCat1 expression in HCC tissues and corresponding normal live tissues by IHC were taken (scale bar = 50 µm). (B) Western blot analysis was used to evaluate the expression of LpCat1 in 6 paired human HCC tissues and adjacent normal tissues. N and C represented adjacent normal parenchyma and cancer tissue, respectively. GAPDH was used as an internal standard. (C, D) The expression of LpCat1 in HCC cell lines was detected by qRT-PCR and western blotting. Data were expressed as mean±SD, *p < 0.05, **p < 0.001. (E, F) qRT-PCR and western blot analysis of LpCat1 levels in Hep3B and Huh7 cells stably transfected with LpCat1-experessed or three shLpCat1 lentivirus vectors. Data were expressed as mean±SD, *p < 0.05, **p < 0.001.

In addition, we detected the mRNA and protein expression levels of LpCat1 in four HCC cell lines and normal liver cell line L02. Similarly, compared to normal liver cells, LpCat1 is generally highly expressed in HCC cell lines (Figures 1C, D). Hep3B and Huh7 cell lines were chose for subsequent experiments. In order to artificially change the expression status of LpCat1, we designed the overexpression and knockdown vectors for LpCat1 and packaged them into lentivirus. Through multiple screening in the in vitro experiments, Hep3B and Huh7 cells with LpCat1 overexpression and knockdown stable transgenic cell sublines were successfully constructed. Efficient depletion or over-expression was evaluated by qRT-PCR and western blot (Figures 1E, F). We chose HCC cells transduced with lentivirus bearing LpCat1 to over-expression and shRNA1 to knockdown LpCat1 expression for subsequent studies.

LpCat1 Promoted The Proliferation, Migration and Invasion of HCC Cells

To confirm the effect of LpCat1 expression on the proliferation of HCC cell lines, we used HCC stably transgenic cell sublines with LpCat1 overexpression or knockdown to perform CCK8 and clone formation assays. The data indicated that the up-regulation of LpCat1 obviously promoted the proliferation of HCC cells compared to the control cells. The proliferation rate was significantly inhibited at 72 h and 96 h in HCC cells with LpCat1 knockdown (Figure 2A). The clone formation assay showed that the number and size of clones of HCC cells were increased in the LpCat1 over-expression group and decreased after knocking down LpCat1 (Figures 2B, C). In summary, LpCat1 plays a key role in maintaining the unlimited proliferation of HCC cells.


Figure 2 LpCat1 promoted the proliferation, migration and invasion of HCC cells. (A) The proliferative ability of Hep3B and Huh7 cells after stably transfection was evaluated by CCK8 assay. (B, C) Neoplastic capacity of Hep3B and Huh7 cells transfected with over-expression or knockdown vectors of LpCat1 was assessed by plate colony formation assay. Cell colonies were counted and analyzed, then showed in histogram. (D, E) Representative images and quantification of transwell assays indicated the migration and invasive capability of HCC cells stably transfected with LpCat1 over-expression or knockdown vectors. The penetrated cells were counted and analyzed, and showed in histogram. (F, G) Wound-healing assays were performed to assess HCC cells migration ability. Wound closure was determined 72 h after the scratch. Data were presented as mean±SD, *p < 0.05, **p < 0.001.

Transwell and wound-healing assays were carried out to explore the effect of LpCat1 expression on the migration and invasion of HCC cells. In the LpCat1 over-expression group, the number of penetrating cells were markedly elevated compared with the control cells (Figures 2D, E), and the wound closed faster than the control cells at 72 h after scratching (Figures 2F, G). Inversely, the number of penetrating shLpCat1-transfected HCC cells was decreased compared with the shMock-transfected cells. The wounds in the shLpCat1-transfected cells closed later than the shMock-transfected cells. Moreover, the expression level of MMP-9 was detected in HCC cell lines with different levels of LpCat1 (Figure 3C). Consistent with the above experimental results, the expression of MMP-9 was positively correlated with LpCat1. Over-expression of LpCat1 enhanced HCC cell mobility accompanied by elevated expression of MMP-9, and vice versa. Therefore, the high expression of LpCat1 contributes to the increased migration and invasion ability of HCC cells.


Figure 3 LpCat1 interacted with STAT1 and facilitates cell cycle progression. (A, B) Flow cytometry analysis of cell cycle in the LpCat1 over-expression and knockdown HCC cells. Data of cell cycle were shown in histograms. Data were presented as mean±SD, *p < 0.05, **p < 0.001. (C, D) The expression of cell cycle related proteins was detected by western blotting in HCC cell lines with LpCat1 stably over-expression or knockdown. GAPDH was used as loading control, and bands were semi-quantitatively analyzed by using Image J software, normalized to GAPDH density. Data were presented as mean±SD, *p < 0.05, **p < 0.001. (E) IP-MS analysis of LpCat1-binding proteins. The proteins of LpCat1 OE and OC groups in Huh7 cells were obtained and performed IPs with anti-LpCat1 antibody. The differential proteins identified by MS analysis between two groups were counted, and the number of genes corresponding to differential proteins was showed in histogram. (F) All these 286 genes were subject to GO term analysis. (G) Enriched KEGG pathway analysis of 286 genes by DAVID. (H) Analyses of identified proteins precipitated with the LpCat1 antibody (Fold change >10). (I) Co-IP analysis indicated the endogenous interaction between LpCat1 and STAT1 proteins in HCC cell lines. (J, K) Western blotting analysis of STAT1 protein in HCC cell lines with LpCat1 stably over-expression or knockdown. GAPDH was used as internal control. Data were presented as mean±SD, *p < 0.05, **p < 0.001.

LpCat1 Facilitated Cell Cycle Progression via Up-Regulation of Cell Cycle Related Proteins

In order to evaluate the influence of LpCat1 expression on the cell cycle of HCC cells, we detected the cell cycle distribution of LpCat1 over-expressed or knocked-down cells by flow cytometry (Figures 3A, B). The results showed that comparing with the knockdown control group, the percentages of G0/G1 phase were increased by 10.66% and 11.18% in the LpCat1 knockdown groups of Hep3B and Huh7 cells, respectively. In the LpCat1 overexpression groups, the percentages of G0/G1-phase were significantly reduced by 6.26% and 11.03%, with the number of cells entering the S phase and G2-M phase increased. These results suggested that the high level of LpCat1 contributed cell cycle progression, inhibition of LpCat1 expression arrested cell cycle at G0/G1 phase.

Taken together, LpCat1 regulates the proliferation and cell cycle of HCC cells, but the accurate molecular mechanism is still unclear. We examined the effect of LpCat1 on cell cycle regulators in HCC cells (Figures 3C, D). Western blotting results indicated that the over-expression of LpCat1 up-regulated the expression of CyclinD1, CyclinE and CDK4, and their expression was dramatically decreased in the HCC cells with LpCat1 knockdown. p27kip1 was reported to be a cell cycle inhibitor in HCC (18). Moreover, we found the expression of p27kip1 is negatively correlated with LpCat1. Thus, induction of LpCat1 overexpression up-regulated CyclinD1, CyclinE and CDK4, but down-regulated p27kip1 in HCC cells. In contrast, the expression of CyclinD1, CyclinE and CDK4 was decreased and p27kip1 was activated in HCC cells with LpCat1 depletion. Accordingly, LpCat1 influences cell cycle to promote HCC proliferation by activating cell cycle-related genes.

LpCat1 Restrained STAT1 Expression by Directly Interacting With STAT1

To explore the proteins interacting with LpCat1, we used the LpCat1 antibody to perform immunoprecipitation (IP) assay and identified targets by mass spectrometry (MS) technology. Totally 286 proteins with abnormal expression were screened out in the LpCat1-overexpressed HCC cells, comparing with the control group of Huh7 cells. Among them, 205 proteins were up-regulated, and 81 proteins were down-regulated (Figure 3E). Then, we analyzed the functions of these 286 dys-regulated genes by using DAVID (The Database for Annotation, Visualization and Integrated Discovery). The top 10 GO terms related to “biological processes”, “molecular functions” and “biological cellular components” are shown in Figure 3F. The predominantly enriched biological process was “single-organism cellular process”. In terms of cellular components, the “membrane-bounded organelle and cytoplasm” biological processes were the most-enriched subcategories. These genes were also enriched in molecular functions included “protein binding”. KEGG pathway analysis showed “cell cycle” was the most enriched subcategories (Figure 3G). Proteins precipitated with the LpCat1 antibody more than 10-fold up-regulation in the LpCat1-overexpressed Huh7 cells were listed in Figure 3H. Among them, STAT1 has been reported to be closely related to the growth and cell cycle of HCC cells. Combining the data of KEGG pathway analysis and cell cycle detection, we speculated that LpCat1 accelerated HCC progression by interaction with STAT1. The direct interaction between LpCat1 and STAT1 was proved by co-IP and western blotting assays in Hep3B and Huh7 cells (Figure 3I).

Based on the interplay of LpCat1 and STAT1, we found the expression of LpCat1 in HCC cells and tissues is significantly negatively correlated with STAT1 (Figures 3J, K, Supplementary Figure 3). As a tumor suppressor gene, STAT1 could inhibit the growth of HCC and induce cell arrest at G0/G1 phase (19). The generally high level of LpCat1 would inhibit the tumor suppressor STAT1, thereby accelerating cell cycle and proliferation of HCC cells.

LpCat1 Promoted Tumorigenesis and Metastasis of HCC In Vivo

In order to examine the effect of LpCat1 on tumor metastasis in vivo, we established metastasis model by implantation of lentivirus-mediated stably transfected Hep3B cells with up- or down-regulation of LpCat1 expression by tail vein injection. Four weeks after injection, the number of lung nodules in the mice of LpCat1 overexpression group was significantly greater than the control group. In the LpCat1 knockdown group of mice, the number of lung nodules was markedly reduced or even absent, which implicated down-regulation of LpCat1 expression could effectively inhibit metastasis of HCC cells in vivo (Figures 4A–C).


Figure 4 LpCat1 promoted tumorigenesis and metastasis in vivo. (A) Hep3B cells stably transfected with different constructs were separately injected into the tail vein of nude mice to form metastasis model. The photo of lungs in each group (n = 6 mice per group) was taken. (B) HE staining showed the pulmonary metastatic nodules of nude mice (scale bar = 50 µm). (C) The numbers of metastatic nodules in the lungs of each mouse were counted and analyzed. The data were expressed as the mean ± SD, *P < 0.05, **P < 0.001. (D) Effect of LpCat1 on liver orthotopic xenograft tumor growth in nude mice. After the observation, mice were sacrificed and the tumors were harvested. (E, F) Tumor volume was calculated and tumor weight was weighed. The data were expressed as the mean ± SD, *P < 0.05. (G) Immunohistochemical examination of the indicated factor expression in the xenograft tumors (scale bar = 50 µm).

In addition, the xenograft model was established to evaluate the effect of LpCat1 on tumor growth. Consistent with the in vitro experimental data, LpCat1 enhanced tumorigenicity of HCC cells in vivo (Figure 4D). Compared with the control group, the tumor volume and weight of the LpCat1 overexpression group significantly increased. The tumor growth was substantially inhibited in the LpCat1 depletion group, as shown by smaller tumor size and lighter tumor weight (Figures 4E, F). Moreover, we detected the expression of LpCat1, STAT1, CyclinD1, ki67 and MMP-9 in the tumor tissues by immunohistochemistry (Figure 4G). In the LpCat1 up-regulated group, the expression of STAT1 was reduced, and the expression of ki67, MMP-9 and CyclinD1 was positively increased, compared with the control group. Conversely, down-regulation of LpCat1 promoted the expression of STAT1, and suppressed the expression of ki67, MMP-9 and CyclinD1. These results suggested that LpCat1 could promote the tumorigenesis and metastasis of HCC in vivo.


The development of HCC was a complex process involving multiple genes. Identifying the key genes maintaining the malignant phenotype would be of great significant for molecular targeted therapy of HCC. Abnormally active of lipid synthesis was observed in HCC pathophysiology (20). However, it was still unclear how these lipid synthesis enzymes contribute to the progression of HCC. Importantly, LpCat1 is an important enzyme responsible for lipid synthesis, which mainly catalyzes the conversion of lysophosphatidylcholine (LPC) into phosphatidylcholine (PC) (21, 22). The molecular lipidomic study of clinical HCC specimens reported that PC species increased in HCC tissues with reduction of LPC, which indicated LpCat1 is closely related to the development of HCC (12). Genomic analysis of LpCat1 copy number in TCGA database revealed LpCat1 gene amplification exists in various tumors, especially lung adenocarcinoma (18%, 40/230), lung squamous cell carcinoma (19%, 94/501), ovarian serous cystadenocarcinoma (14%, 79/579), esophageal carcinoma (13%, 23/184) and so on (2325). LpCat1 was generally recognized as an oncogene due to its up-regulation in a variety of tumor tissues including HCC. In our study, we firstly confirmed that LpCat1 was overexpressed in HCC tissues and HCC cells lines. LpCat1 protein expression level in HCC patients was significantly correlated with the vascular invasion and the TNM stage. Our experimental results showed that the high expression of LpCAT1 could be accompanied by an increase in the expression of matrix metalloproteinase (MMP-9). Accumulating studies confirmed that MMP-9 could facilitate the migration of tumor cells and cross-vascular invasion by dissolving extracellular matrix, thereby ultimately forming in situ and remote metastasis (26). It can also explain that HCC patients with an elevated expression of LpCAT1 were related to vascular invasion and advanced tumor staging. Moreover, Zhou et al. found that the expression of LpCat1 was positively correlated with the progression of prostate cancer (27). Another study showed that LpCat1 was expressed at least in normal breast tissues, relatively elevated in fibrocystic breast tissues, and most expressed in primary breast cancer tissues (8). Collectively, high level of LpCat1 promoted tumor progression, which might be a potential therapeutic target for HCC.

To understand the role of LpCat1 in the development of HCC, we evaluated the impact of altered levels of LpCat1 on the proliferation and metastasis of HCC in vitro and in vivo. Our data showed that the overexpression of LpCat1 enhanced viability and motility of HCC cells, while the down-regulation of LpCat1 inhibited cell proliferation, migration and invasion potential. Of note, with the knockdown of LpCat1, the number of lung nodules was decreased or even absent in metastasis model of mice, and the liver tumors of mice were smaller and lighter in xenograft model. These results indicated that down-regulation of LpCat1 effectively inhibited the growth and metastasis of HCC. Similarly, knockdown of LpCat1 showed not only cellular proliferation but also invasiveness and migration were both repressed in oral squamous cell carcinoma (9). Reduction of LpCat1 level in lung adenocarcinoma obviously restrained tumor growth and brain metastases in vivo (11). In clear cell renal cell carcinoma cells, depletion of LpCat1 decreased PCs, inhibited biological phenotype of cancer cells, and induced cell cycle arrest at G0/G1 phase (10). Furthermore, we investigated the effect of LpCat1 on cell cycle of HCC cells. LpCat1 accelerated cell cycle progression and knockdown of LpCat1 arrested cell cycle at G0/G1 phase in HCC cells, which was in consistent with the previous reported results.

To explore the underlying molecular mechanism of LpCat1 in HCC, we detected a series of cancer-related genes. The expression of cell cycle-related genes including CyclinD1, CyclinE and CDK4 were positively correlated with LpCat1 level in HCC cells. Moreover, LpCat1 could reduce the level of p27kip1, which was commonly recognized as a cell cycle inhibitor (28, 29). These results indicated that LpCat1 could accelerate cell cycle to maintain the aggressive proliferation of HCC cells by regulating the cell cycle-related genes expression. MMP-9, one of the cell metastatic markers (30), was found obviously increased in the LpCat1 over-expressed HCC cells and tissues. IHC analysis showed LpCat1 up-regulation increased ki67 expression in xenograft tumors. These findings suggested that LpCat1 promoted HCC cell proliferation, migration, invasion and cell cycle progression through activating several cancer-related genes. To clarify how LpCat1 affects these factors, we explored the proteins binding to LpCat1 in HCC cells. Based on IP-tandem LC/MS technology, we identified a variety of proteins, which were suspected to interact with LpCat1. Analyzing the results, STAT1 was predicted to be the interacting target with LpCat1, and we proved the direct interaction between STAT1 and LpCat1 in HCC cells by co-IP. As an important signal transduction factor, STAT1 was usually considered as a tumor suppressor in multiple cancers including HCC (3134). Chen et al. reported STAT1 induced G0/G1 cell cycle arrest through reduction of cell cycle regulators including CyclinA, CyclinD1, CyclinE and CDK2 in HCC cells (35). In addition, researchers have also shown that the enhanced STAT1 expression in fibrosarcoma cells could restrain tumor formation and metastasis in mice by down-regulation of MMP-2 and MMP-9 (36). Consistent with our previous speculation, the present results demonstrated that up-regulation of STAT1 caused by LpCat1 knockdown inhibited cell proliferation, migration and invasion, arrested cell cycle at G0/G1 phase, accompanying by promotion of CyclinD1, CyclinE, CDK4 and MMP-9 levels, but a reduction of p27kip1 expression. In addition, we detected the expression of the phosphorylation state of STAT1 in Hep3B and Huh7 cells by western blotting, but got the negative results. STAT1 was predominantly present in unphosphorylated state in HCC cells, which had been confirmed by previous studies (37). Therefore, LpCat1 contributed to the development of HCC by directly interacting with STAT1.

In conclusion, we identified LpCat1 was significantly over-expressed in HCC tissues and cancer cells. Our study demonstrated that LpCat1 could directly interact with STAT1 and negatively regulate its expression level. High levels of LpCat1 not only promoted the expression of CyclinD1, CyclinE and CDK4, reduced the level of p27kip1 to accelerate the cell cycle process and cell proliferation, but also enhanced the cell migration and invasion by up-regulation of MMP-9. Conversely, STAT1 was released and increased in HCC cells with LpCat1 knockdown, contributing to cell cycle arrest at G0/G1 phase and inhibition of cell metastasis. Furthermore, what are the regulatory factors upstream of LpCat1? How to regulate? No relevant reports have been revealed so far, and we need to conduct in-depth research in the future. Overall, LpCat1 contributed to progressive HCC cell growth and metastasis. Knockdown of LpCat1 showed a strong inhibitory effect on the growth and metastasis of HCC in vivo and in vitro. In conclusion, LpCat1 might be a novel potential target for diagnosis and treatment of HCC.

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics Statement

The studies involving human participants were reviewed and approved by Committee on Ethics of Medicine, Navy Military Medical University (Shanghai, China). The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Animal Ethics Committee of Navy Military Medical University (Shanghai, China).

Author Contributions

CS and MG conceived and designed this study. WJ, ZP, and BS performed the main experiments. LC assisted with the xenograft model construction in mice. QZ assisted with the statistical analysis of data. WJ wrote the original draft. ZP and BS reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.


This study was financially supported by grants from the National Key Research and Development Program of China (No. 2018YFA0900900).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at:

Supplementary Figure 1 | Cellular immunofluorescence was used to observe EGFP positive HCC cells at 72 h after infection with lentiviral vectors mediating LpCat1 overexpression or knockdown.

Supplementary Figure 2 | qRT-PCR analysis of LpCat1 expression in HCC tissues and corresponding normal tissues (n=40).

Supplementary Figure 3 | The expression level of STAT1 was detected by tissue microarray-based immunohistochemical analysis in HCC tissues. The representative images of STAT1 expression in HCC tissues and corresponding normal live tissues by IHC were taken, scale bar = 50 µm.


1. Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, et al. Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metab (2019) 30(3):525–38. doi: 10.1016/j.cmet.2019.06.014

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Friedman JS, Chang B, Krauth DS, Lopez I, Waseem NH, Hurd RE, et al. Loss of Lysophosphatidylcholine Acyltransferase 1 Leads to Photoreceptor Degeneration in rd11 Mice. Proc Natl Acad Sci USA (2010) 107(35):15523–8. doi: 10.1073/pnas.1002897107

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Johnson AA, Stolzing A. The Role of Lipid Metabolism in Aging, Lifespan Regulation, and Age-Related Disease. Aging Cell (2019) 18(6):e13048. doi: 10.1111/acel.13048

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Szlasa W, Zendran I, Zalesińska A, Tarek M, Kulbacka J. Lipid Composition of the Cancer Cell Membrane. J Bioenerg Biomembr (2020) 52(5):321–42. doi: 10.1007/s10863-020-09846-4

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Wang B, Tontonoz P. Phospholipid Remodeling in Physiology and Disease. Annu Rev Physio (2019) 81:165–88. doi: 10.1146/annurev-physiol-020518-114444

CrossRef Full Text | Google Scholar

6. Grupp K, Sanader S, Sirma H, Simon R, Koop C, Prien K, et al. High Lysophosphatidylcholine Acyltransferase 1 Expression Independently Predicts High Risk for Biochemical Recurrence in Prostate Cancers. Mol Oncol (2013) 7(6):1001–11. doi: 10.1016/j.molonc.2013.07.009

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Uehara T, Kikuchi H, Miyazaki S, Iino I, Setoguchi, et al. Overexpression of Lysophosphatidylcholine Acyltransferase 1 and Concomitant Lipid Alterations in Gastric Cancer. Ann Surg Oncol (2016) 23(Suppl 2):S206–213. doi: 10.1245/s10434-015-4459-6

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Abdelzaher E, Mostafa MF. Lysophosphatidylcholine Acyltransferase 1(LPCAT1) Upregulation in Breast Carcinoma Contributes to Tumor Progression and Predicts Early Tumor Recurrence. Tumour Biol (2015) 36(7):5473–83. doi: 10.1007/s13277-015-3214-8

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Shida-Sakazume T, Endo-Sakamoto Y, Unozawa M, Fukumoto C, Shimada K, Kasamatsu A, et al. Lysophosphatidylcholine Acyltransferase1 Overexpression Promotes Oral Squamous Cell Carcinoma Progression Via Enhanced Biosynthesis of Platelet-Activating Factor. PloS One (2015) 10(3):e0120143. doi: 10.1371/journal.pone.0120143

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Du Y, Wang Q, Zhang X, Wang X, Qin C, Sheng Z, et al. Lysophosphatidylcholine Acyltransferase 1 Upregulation and Concomitant Phospholipid Alterations in Clear Cell Renal Cell Carcinoma. J Exp Clin Cancer Res (2017) 36(1):66. doi: 10.1186/s13046-017-0525-1

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Wei C, Dong X, Lu H, Tong F, Chen L, Zhang R, et al. LPCAT1 Promotes Brain Metastasis of Lung Adenocarcinoma by Up-Regulating PI3K/AKT/MYC Pathway. J Exp Clin Cancer Res (2019) 38(1):95. doi: 10.1186/s13046-019-1092-4

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Morita Y, Sakaguchi T, Ikegami K, Goto-Inoue N, Hayasaka T, Hang VT, et al. Lysophosphatidylcholine Acyltransferase 1 Altered Phospholipid Composition and Regulated Hepatoma Progression. J Hepatol (2013) 59(2):292–9. doi: 10.1016/j.jhep.2013.02.030

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, et al. The Potential and Controversy of Targeting STAT Family Members in Cancer. Semin Cancer Biol (2020) 60:41–56. doi: 10.1016/j.semcancer.2019.10.002

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease. Cell (1996) 84(3):443–50. doi: 10.1016/s0092-8674(00)81289-1

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Tymoszuk P, Charoentong P, Hackl H, Spilka R, Müller-Holzner E, Trajanoski Z, et al. High STAT1 mRNA Levels But Not its Tyrosine Phosphorylation are Associated With Macrophage Infiltration and Bad Prognosis in Breast Cancer. BMC Cancer (2014) 14:257. doi: 10.1186/1471-2407-14-257

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Ni W, Zhang Y, Zhan Z, Ye F, Liang Y, Huang J, et al. A Novel lncRNA uc.134 Represses Hepatocellular Carcinoma Progression by Inhibiting CUL4A-mediated Ubiquitination of LATS1. J Hematol Oncol (2017) 10(1):91. doi: 10.1186/s13045-017-0449-4

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Yi B, Qiu Y, Ji W, Wei M, Liu C, Peng Z, et al. Desulfation of Cell Surface HSPG is an Effective Strategy for the Treatment of Gallbladder Carcinoma. Cancer Lett (2016) 381(2):349–58. doi: 10.1016/j.canlet.2016.08.002

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Tuo L, Xiang J, Pan X, Hu J, Tang H, Liang L, et al. PCK1 Negatively Regulates Cell Cycle Progression and Hepatoma Cell Proliferation Via the AMPK/p27 Kip1 Axis. J Exp Clin Cancer Res (2019) 38(1):50. doi: 10.1186/s13046-019-1029-y

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Chen J, Wang H, Wang J, Huang S, Zhang W. STAT1 Inhibits Human Hepatocellular Carcinoma Cell Growth Through Induction of p53 and Fbxw7. Cancer Cell Int (2015) 15:111. doi: 10.1186/s12935-015-0253-6

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Beyoğlu D, Idle JR. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy. Metabolites (2020) 10(2):50. doi: 10.3390/metabo10020050

CrossRef Full Text | Google Scholar

21. Law SH, Chan ML, Marathe GK, Parveen F, Chen CH, Ke LY. An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. Int J Mol Sci (2019) 20(5):1149. doi: 10.3390/ijms20051149

CrossRef Full Text | Google Scholar

22. Soupene E, Kuypers FA. Phosphatidylcholine Formation by LPCAT1 is Regulated by Ca(2+) and the Redox Status of the Cell. BMC Biochem (2012) 13:8. doi: 10.1186/1471-2091-13-8

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B, et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discovery (2012) 2(5):401–4. doi: 10.1158/2159-8290.CD-12-0095

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer S, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the Cbioportal. Sci Signal (2013) 6(269):pl1. doi: 10.1126/scisignal.2004088

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Mansilla F, da Costa KA, Wang S, Kruhøffer M, Lewin TM, Orntoft TF, et al. Lysophosphatidylcholine Acyltransferase 1 (LPCAT1) Overexpression in Human Colorectal Cancer. J Mol Med (Berl) (2009) 87(1):85–97. doi: 10.1007/s00109-008-0409-0

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Deryugina EI, Quigley JP. Matrix Metalloproteinases And Tumor Metastasis. Cancer Metastasis Rev (2006) 25(1):29–34. doi: 10.1007/s10555-006-7886-9

CrossRef Full Text | Google Scholar

27. Zhou X, Lawrence TJ, He Z, Pound CR, Mao J, Bigler SA. The Expression Level of Lysophosphatidylcholine Acyltransferase 1 (LPCAT1) Correlates to the Progression of Prostate Cancer. Exp Mol Pathol (2012) 92(1):105–10. doi: 10.1016/j.yexmp.2011.11.001

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Cai X, Hu X, Cai B, Wang Q, Li Y, Tan X, et al. Metformin Suppresses Hepatocellular Carcinoma Cell Growth Through Induction of Cell Cycle G1/G0 Phase Arrest and p21CIP and p27KIP Expression and Downregulation of Cyclin D1 In Vitro and In Vivo. Oncol Rep (2013) 30(5):2449–57. doi: 10.3892/or.2013.2718

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Kumar P, Wood C. Kaposi’s Sarcoma-Associated Herpesvirus Transactivator Rta Induces Cell Cycle Arrest in G0/G1 Phase by Stabilizing and Promoting Nuclear Localization of P27kip. J Virol (2013) 87(24):13226–38. doi: 10.1128/JVI.02540-13

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, Han JW, et al. Lysophosphatidic Acid Augments Human Hepatocellular Carcinoma Cell Invasion Through LPA1 Receptor and MMP-9 Expression. Oncogene (2011) 30(11):1351–9. doi: 10.1038/onc.2010.517

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Huang J, Zheng C, Shao J, Chen L, Liu X, Shao J. Overexpression of eEF1A1 Regulates G1-phase Progression to Promote HCC Proliferation Through the STAT1-cyclin D1 Pathway. Biochem Biophys Res Commun (2017) 494(3-4):542–9. doi: 10.1016/j.bbrc.2017.10.116

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Dorritie KA, Mccubrey JA, Johnson DE. STAT Transcription Factors in Hematopoiesis and Leukemogenesis: Opportunities for Therapeutic Intervention. Leukemia (2014) 28(2):248–57. doi: 10.1038/leu.2013.192

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Zhang X, Li X, Tan F, Yu N, Pei H. STAT1 Inhibits miR-181a Expression to Suppress Colorectal Cancer Cell Proliferation Through PTEN/Akt. J Cell Biochem (2017) 118(10):3435–43. doi: 10.1002/jcb.26000

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, et al. STAT1-Deficient Mice Spontaneously Develop Estrogen Receptor Alpha-Positive Luminal Mammary Carcinomas. Breast Cancer Res(2012) 14(1):R16. doi: 10.1186/bcr3100

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Chen G, Wang H, Xie S, Ma J, Wang G. STAT1 Negatively Regulates Hepatocellular Carcinoma Cell Proliferation. Oncol Rep (2013) 29:2303–10. doi: 10.3892/or.2013.2398

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, Mcclary C, et al. Cooperativity of the MUC1 Oncoprotein and STAT1 Pathway in Poor Prognosis Human Breast Cancer. Oncogene (2010) 29(6):920–9. doi: 10.1038/onc.2009.391

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Ma B, Chen K, Liu P, Li M, Liu J, Sideras K, et al. Dichotomal Functions of Phosphorylated and Unphosphorylated STAT1 in Hepatocellular Carcinoma. J Mol Med (Berl) (2019) 97(1):77–88. doi: 10.1007/s00109-018-1717-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: LpCat1, STAT1, cell cycle, proliferation, metastasis, hepatocellular carcinoma (HCC)

Citation: Ji W, Peng Z, Sun B, Chen L, Zhang Q, Guo M and Su C (2021) LpCat1 Promotes Malignant Transformation of Hepatocellular Carcinoma Cells by Directly Suppressing STAT1. Front. Oncol. 11:678714. doi: 10.3389/fonc.2021.678714

Received: 12 March 2021; Accepted: 18 May 2021;
Published: 04 June 2021.

Edited by:

Mingyan Zhu, Affiliated Hospital of Nantong University, China

Reviewed by:

Yuhua Shi, Yancheng Third People’s Hospital, China
Yao Zhang, Nanjing Medical University, China

Copyright © 2021 Ji, Peng, Sun, Chen, Zhang, Guo and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Changqing Su,; Minggao Guo,

These authors have contributed equally to this work